Posted in Testosterone treatment, tagged advanced prostate cancer, Bone loss, BUSINESSWIRE, cancer research, castrate level, catheter, comparison of treatments, GTx-758, hot flashes, LHRH analogs, orchiectomy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate treatment, prostate treatment debate on August 15, 2010| Leave a Comment »
BUSINESSWIRE: The results of phase 2 (there are three) trials of a new drug that reduces testosterone to castrate levels and serum free testosterone to levels lower than orchiectomy or LHRH analogs – without bone loss or hot flashes- are about to be reported in the US. READ MORE>
Posted in Hormone therapy, PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, tagged advanced prostate cancer, androgen-deprivation therapy, cancer research, catheter, Hormone therapy, long-term androgen deprivation therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, recovery of testosterone, URO TODAY on June 12, 2010| Leave a Comment »
URO TODAY: The recovery of testosterone after long-term androgen deprivation therapy for prostate cancer is slow, according to a study of about 20 patients who had been receiving hormone drugs for a mean seven years. READ MORE>
Posted in PROSTATE CANCER, PROSTATE RESEARCH, PROSTATE RISKS, PSA tests, Testosterone treatment, Treatment news, Uncategorized, tagged androgen-deprivation therapy, cancer research, cause of prostate cancer, decrease in prostate volume, disappearance of cancerous cells, Hormone therapy, interventional radiological procedure, Israel, Maynei Hayeshua medical center, medical scientists in Israel, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, PSA, PSA test, Radiotherapy, Rehovot, repeat biopsies, super-selective intraprostatic androgen deprivation therapy, testicular and prostate venous (blood) drainage systems, testosterone leaks, URO TODAY, very highly concentrated testosterone, Weizmann Institute of Science on October 6, 2009| Leave a Comment »
URO TODAY: It’s very early days, but medical scientists in Israel may have made a new discovery about the cause of prostate cancer and subsequently how to treat it. READ MORE>
They believe that as men age, very highly concentrated testosterone leaks to the prostate gland via the testicular and prostate venous (blood) drainage systems.
They tried treating six men with an “interventional radiological procedure and super-selective intraprostatic androgen deprivation therapy” and in five cases achieved a decrease in prostate size and in PSA levels, with repeat biopsies showing disappearance of cancerous cells.
The work is being done at Maynei Hayeshua medical center and Department of Condensed Matter Physics, Weizmann Institute of Science, Rehovot, Israel.
At NEW PROSTATE CANCER INFOLINK, Mike Scott writes:
This is clearly a radical new finding that needs to be confirmed by other research groups.
Should it prove to be accurate, we may have a whole new mechanism available to treat early stage disease without having to expose patients to systemic forms of hormone therapy.
The “New” Prostate Cancer InfoLink emphasizes, however, that we have seen only an abstract of this report, and we need greater detail to understand what is actually being suggested by Gat and colleagues. READ MORE>
Posted in Bone loss, PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, Treatment news, tagged advanced prostate cancer, androgen-deprivation therapy, Bone loss, cancer research, Hormone therapy, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, slow-release drugs, testes removal, testicular prostheses, testosterone control, URO TODAY on September 15, 2009| Leave a Comment »
URO TODAY: Testicular prostheses that slow-release drugs to combat bone loss in men being treated for advanced prostate cancer, have the potential to restore testes removal as a viable option for testosterone control. READ MORE>
Posted in Diagnosis, Hormone therapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, PROSTATE RISKS, Testosterone treatment, Treatment debate, tagged advanced stage of presentation, androgen-deprivation therapy, cancer research, high Gleason score, high serum testosterone, Hormone therapy, increased risk of biochemical recurrence after surgery, low serum testosterone, new testosterone evidence, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, testosterone, testosterone levels, URO TODAY, worrisome cancer features on September 6, 2009| Leave a Comment »
URO TODAY: High levels of testosterone have until recently been regarded as dangerous for prostate cancer patients, but new evidence is emerging that suggests something different. READ MORE>
Provocative new evidence suggests that it is not high serum testosterone that is problematic for prostate cancer, but low serum testosterone that is associated with worrisome cancer features and outcomes, such as high Gleason score, advanced stage of presentation, and increased risk of biochemical recurrence after surgery.
Posted in Hormone therapy, New prostate drugs, PROSTATE CANCER, PROSTATE RESEARCH, Testosterone treatment, Treatment news, tagged advanced prostate cancer, allergic reactions, cancer research, Degarelix, gonadotrophin-releasing hormone antagonist/receptor blocker, hormonal treatment, prostablog, prostate, prostate blog, PROSTATE CANCER, prostate cancer treatments, prostate treatment, prostate treatment debate, Swedish research, URO TODAY, well tolerated on August 16, 2009| Leave a Comment »
URO TODAY: Swedish research shows a new treatment for advanced prostate cancer, the gonadotrophin-releasing hormone antagonist/receptor blocker Degarelix, is well tolerated, with no systemic allergic reactions. READ MORE>
This new agent represents an important pharmacological development in the hormonal treatment of prostate cancer.
Prostablog RSS – click here